Abstract

BACTERIOLOGICAL PROFILE AND DRUG SUSCEPTIBILITY PATTERN IN INTENSIVE CARE UNITS OF A TERTIARY CARE HOSPITAL

Dr. Seema Mittal*, Diksha Budhani, Surinder Kumar, Raminder Sandhu and Sumit Kumar

ABSTRACT

Background: Multi-drug resistant infections are one of the leading causes of deaths and morbidity amongst hospitalized patients throughout the world. Objective: The objective of this study was to know the Bacteriological profile and antibiotic resistance pattern of the common isolates from blood, urine, fluid, sputum and pus/wound swab of patients admitted in ICU of a tertiary care hospital. Methods: The study was conducted in the different Intensive Care Units of a tertiary care public hospital during January 2017 to Dec 2018. Patients admitted in any of the four ICUs of the hospital who were clinically suspected of having acquired any infection were included. Depending on the clinical suspicion laboratory samples were collected from the patients. Samples were subjected to the testing and antibiotic sensitivity. Results: The commonest organism isolated from all samples was Klebsiella spp. 43(27.38) followed by E.coli 34 (21.65). In NICU, majority Klebsiella 20(33.89) was predominantly isolated. In SICU, E.coli 24(30.37) was predominantly isolated. In MICU, E.coli 7(36.84) followed by Klebsiella spp.6 (31.57) were predominantly isolated. Klebsiella sp. is most commonly sensitive to Meropenem 32(74.41) followed by piperacillin tazobactam 25(58.13) E.coli is most commonly sensitive to Meropenem 18(52.94) followed by Amikacin 17(50), majority of Citrobacter spp. was also sensitive to Meropenem 15 (46.87), Psudomonas was commonly sensitive to Piperacillin+Tazobactum 10(76.92), S.aureus was sensitive to both vancomycin 17(100) and linezolid 17(100) respectively. Conclusion: The findings of this study might help clinicians to formulate their first line empirical antibiotic treatment regimens for the patients admitted in ICUs.

Keywords: Intensive care units, antimicrobial resistance pattern, nosocomial infection.